Loading clinical trials...
Loading clinical trials...
A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Conditions
Interventions
Sintilimab
IBI310&Sintilimab
+1 more
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
May 25, 2023
Primary Completion Date
April 15, 2028
Completion Date
July 15, 2028
Last Updated
March 15, 2024
NCT06898450
NCT06974110
NCT05426005
NCT06580574
NCT03983993
NCT04556253
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions